MAP2 immunoreactivity deficit is conserved across the cerebral cortex within individuals with schizophrenia

Area of Science:

• Neuroscience
• Psychiatry
• Cell Biology

Background:

• Previous studies indicate reduced microtubule-associated protein 2 (MAP2) immunoreactivity (IR) in schizophrenia (SZ).
• The regional consistency of MAP2-IR deficits within individuals with SZ remains largely uncharacterized.

Purpose of the Study:

• To investigate the pattern of MAP2-IR across distinct cortical regions in individuals with and without SZ.
• To determine if MAP2-IR deficits in SZ are regionally specific or widespread within an individual.

Main Methods:

• Quantitative fluorescence microscopy was used to measure MAP2-IR in deep layer 3 of the dorsolateral prefrontal cortex (DLPFC), lateral intraparietal cortex (LIP), and primary visual cortex (V1).
• Postmortem brain tissue from 20 pairs of SZ subjects and matched nonpsychiatric comparison (NPC) subjects was analyzed.

Main Results:

• Significantly lower MAP2-IR was observed in SZ subjects compared to NPC subjects across all three regions.
• No significant region-by-diagnosis interaction was found, indicating consistent deficits.
• Within-pair ratios of MAP2-IR were significantly correlated across the DLPFC, LIP, and V1.

Conclusions:

• MAP2-IR deficits in schizophrenia are not region-specific but are consistent across multiple neocortical areas within individuals.
• These findings suggest a generalized pathology affecting MAP2 in SZ.
• The consistent pattern of MAP2-IR deficits has implications for understanding schizophrenia pathophysiology and developing targeted therapies.